ISRCTN ISRCTN47999700
DOI https://doi.org/10.1186/ISRCTN47999700
IRAS number 1012021
Secondary identifying numbers Quotient code QSC303166
Submission date
01/09/2025
Registration date
02/09/2025
Last edited
02/09/2025
Recruitment status
Not yet recruiting
Overall study status
Deferred
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Contact information

Dr Litza McKenzie
Principal Investigator

Quotient Sciences Limited, Mere Way, Ruddington Fields, Ruddington
Nottingham
NG11 6JS
United Kingdom

Phone +44 (0) 330 303 1000
Email recruitment@weneedyou.co.uk
Dr . Novartis Study Director
Public, Scientific

Lichtstrasse 35
Basel
4056
Switzerland

Phone +41 61 324 11 11
Email novartis.email@novartis.com

Study information

Study designPharmacokinetic and food effect study in healthy volunteers
Primary study designInterventional
Secondary study designPartially randomised study
Study setting(s)Pharmaceutical testing facility
Study typeOther
Participant information sheet Not available in web format, please use contact details to request a participant information sheet.
Scientific titlePhase I Study: Quotient Code QSC303166 [the full scientific title will be published within 30 months after the end of the trial]
Study acronymNot applicable
Study objectivesThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Ethics approval(s)

Submitted 01/07/2025, Wales Research Ethics Committee 2 (Health and Care Research Wales, Castlebridge 5, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 2920 230 457; Wales.REC2@wales.nhs.uk), ref: 25/WA/0163

Health condition(s) or problem(s) studiedThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.
InterventionThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.
Intervention typeDrug
Pharmaceutical study type(s)Pharmacokinetic
PhasePhase I
Drug / device / biological / vaccine name(s)The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.
Primary outcome measureThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.
Secondary outcome measuresThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.
Overall study start date01/07/2025
Completion date30/03/2026

Eligibility

Participant type(s)Healthy volunteer
Age groupAdult
SexBoth
Target number of participants64
Key inclusion criteriaThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.
Key exclusion criteriaThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.
Date of first enrolment05/09/2025
Date of final enrolment30/03/2026

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Quotient Sciences Limited
Mere Way, Ruddington Fields, Ruddington
Nottingham
NG11 6JS
United Kingdom

Sponsor information

Novartis Pharmaceuticals UK Limited
Industry

2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane
London
W12 7FQ
England
United Kingdom

Phone +41 61 324 11 11
Email novartis.email@novartis.com

Funders

Funder type

Industry

Novartis Pharmaceuticals UK Limited
Private sector organisation / For-profit companies (industry)
Alternative name(s)
Novartis UK, NOVARTIS UK LIMITED
Location
United Kingdom

Results and Publications

Intention to publish date30/09/2028
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planFull trial details will be published up to 30 months after the end of the trial. Publication of some of the trial details is deferred because of the high commercial sensitivity of this Phase I study and the negligible benefit to the public of Phase I information. Results may be posted on or after the date of publication of trial details.
IPD sharing planNot expected to be made available

Editorial Notes

01/09/2025: Trial's existence confirmed by MHRA.